Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
Bringing faster healthier wound healing outcomes to trauma, burn victims and diabe...
Bringing faster healthier wound healing outcome...
ANGLE is a world leading liquid biopsy company with pioneering products in cancer ...
ANGLE is a world leading liquid biopsy company ...
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its diffe...
Mersana Therapeutics is a clinical-stage biopha...
Sunesis is a biopharmaceutical company focused on the development and commercializ...
Sunesis is a biopharmaceutical company focused ...
Syros is redefining the power of small molecules to control the expression of gene...
Syros is redefining the power of small molecule...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a significant return for its shareho...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a...
Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...
Adaptimmune is a leader in TCR T-cell therapy, ...
Predictive Oncology is a clinical and translational data pipeline and AI-driven pl...
Predictive Oncology is a clinical and translati...
ASLAN Pharmaceuticals is a clinical-stage oncology-focused biotechnology company d...
ASLAN Pharmaceuticals is a clinical-stage oncol...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX)...
Join the National Investor Network and get the latest information with your interests in mind.